세계의 혈액 세포 인자 시장 : 제품 유형별, 소스별, 용도별, 투여 경로별, 최종사용자별, 지역별

Global Blood Cell Factors Market is estimated to be valued at USD 3.37 Bn in 2025 and is expected to reach USD 4.31 Bn by 2032, growing at a compound annual growth rate (CAGR) of 3.6% from 2025 to 2032.

The global blood cell factors market has emerged as a critical component of the healthcare industry, playing a vital role in the treatment and management of various hematological disorders. Blood cell factors are essential proteins and molecules that regulate the growth, differentiation, and function of blood cells, including red blood cells, white blood cells, and platelets. These factors have gained significant attention in recent years due to their potential in treating a wide range of blood-related diseases, such as anemia, leukemia, and thrombocytopenia. The market for blood cell factors is driven by the increasing prevalence of hematological disorders, advancements in biotechnology and pharmaceutical research, and the growing demand for effective and targeted therapies. This article aims to provide a comprehensive overview of the global blood cell factors market, highlighting its current state, key drivers, challenges, and future prospects.

Market Dynamics:

The global blood cell factors market is influenced by several key drivers, restraints, and opportunities. One of the primary drivers is the rising incidence of hematological disorders worldwide, such as anemia, leukemia, and lymphoma. The increasing prevalence of these diseases has created a significant demand for effective treatments, including blood cell factors. Additionally, the growing aging population, which is more susceptible to blood-related disorders, has further fueled the market growth. Advancements in biotechnology and pharmaceutical research have also played a crucial role in driving the market, enabling the development of novel and targeted therapies. However, the market also faces certain restraints, such as the high cost of research and development, stringent regulatory requirements, and the potential side effects associated with blood cell factor therapies. These challenges can hinder the adoption and accessibility of these treatments. Despite these restraints, the market presents significant opportunities for growth and innovation. The increasing focus on personalized medicine, the development of biosimilars, and the expansion of healthcare infrastructure in emerging economies are expected to create new avenues for market players. Moreover, collaborations between pharmaceutical companies, research institutions, and government organizations are likely to accelerate the development and commercialization of blood cell factor therapies, thereby driving market growth in the coming years.

Key features of the study:

• This report provides in-depth analysis of the global blood cell factors market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global blood cell factors market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Amgen Inc., Johnson & Johnson, Roche Holding AG, Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., Sanofi S.A., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Celgene Corporation, Takeda Pharmaceutical Company Limited, and Regeneron Pharmaceuticals, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global blood cell factors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global blood cell factors market.

Market Segmentation

• Product Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Erythropoietin Stimulating Agents (ESAs)
  • Granulocyte Colony-Stimulating Factor (G-CSF)
  • Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
  • Thrombopoietin Receptor Agonists
  • Stem Cell Factor
  • Other Blood Cell Factors (e.g. Interleukins)
• Source Insights (Revenue, USD Bn, 2020 - 2032)
  • Recombinant (rDNA technology-derived)
  • Natural (Plasma-derived)
• Application Insights (Revenue, USD Bn, 2020 - 2032)
  • Oncology
  • Nephrology
  • Hematology Disorders
  • Infectious Diseases
  • Autoimmune Disorders
  • Others (e.g., HIV-related anemia)
• Route Of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Injectable
  • Oral
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Ambulatory Surgical Centers
  • Home Healthcare
  • Specialty Clinics
  • Research & Academic Institutes
  • Others
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Amgen Inc.
  • Johnson & Johnson
  • Roche Holding AG
  • Novartis AG
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Celgene Corporation
  • Takeda Pharmaceutical Company Limited
  • Regeneron Pharmaceuticals, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Blood Cell Factors Market, By Product Type
  • Global Blood Cell Factors Market, By Source
  • Global Blood Cell Factors Market, By Application
  • Global Blood Cell Factors Market, By Route of Administration
  • Global Blood Cell Factors Market, By End user
  • Global Blood Cell Factors Market, By Region

3. Market Dynamics, Regulations, And Trends Analysis

• Market Dynamics
  • Driver
  • Restraint
  • Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Blood Cell Factors Market, By Product Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Erythropoietin Stimulating Agents (ESAs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Granulocyte Colony-Stimulating Factor (G-CSF)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Thrombopoietin Receptor Agonists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Stem Cell Factor
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other Blood Cell Factors (e.g. Interleukins)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Blood Cell Factors Market, By Source, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Recombinant (rDNA technology-derived)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Natural (Plasma-derived)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Blood Cell Factors Market, By Application, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Nephrology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Hematology Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Infectious Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Autoimmune Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others (e.g., HIV-related anemia)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Blood Cell Factors Market, By Route of Administration, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Blood Cell Factors Market, By End User, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Ambulatory Surgical Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Home Healthcare
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Research & Academic Institutes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Blood Cell Factors Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End user, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End user, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End user, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End user, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End user, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End user, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Roche Holding AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Gilead Sciences, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi S.A.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Celgene Corporation
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Regeneron Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us